Cancer patients are to take part in a pioneering research trial run by Oxford University leaders.
One group will take increasing dosages of a new drug CXD101, which is known as a histone deacetylase (HDAC) inhibitor that kills cancer cells by blocking the functions of HDAC enzymes in the body.
The enzymes are needed for cell multiplication, migration and survival so blocking them can stop tumours spreading.
The second will be tested for the HR23B protein that could determine the effectiveness of CXD101 and similar drugs and those with high levels will get the most appropriate dose of CXD101.
The trial is being held with Oxford University Hospitals NHS Trust and 30 to 40 cancer patients. University department of oncology lead researcher Professor Nick La Thangue said: “HDAC inhibitors have had limited success in the past, but CXD101 works in a new way and has great potential to treat many different cancers.”
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules hereComments are closed on this article